CUVL offering history
Every offering-related filing in Clinuvel Pharmaceuticals Ltd’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 49 filings back to May 7, 2004.
| Date | Filing | What it means | |
|---|---|---|---|
| Jul 17, 2026 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Aug 16, 2021 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Nov 26, 2010 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Mar 20, 2006 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
Two honest limits. (1) A 424B takedown can price shares or notes — EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
CUVL offering FAQ
When did CUVL last execute an offering?
No executed-offering document (424B pricing supplement or 8-K item 3.02) appears in the 49 filings EDGAR returns for Clinuvel Pharmaceuticals Ltd, reviewed back to 2004-05-07.
When did CUVL last announce or register an offering?
No offering registration (S-1/S-3/F-1/F-3) appears in the filings reviewed back to 2004-05-07.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.
Free to use. No account, no card.